MedElevator
Войти в исследования Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2025
Long Term Outcomes of Paediatric Epistaxis Management-Follow-Up From a 4-Year Prospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Loh Charlotte, Crotty Thomas J, Alshammasi Raghad, Garry Stephen, Heffernan Colleen B
Аннотация
INTRODUCTION: Recurrent paediatric epistaxis is a common condition that is often distressing for children and their caregivers. Although treatments such as Naseptin or silver nitrate cautery are widely used, a recurrence of epistaxis after an initial symptom-free period is frequent. Yet, there is a lack of robust, long-term studies comparing treatment modalities and sustained success rates. This study aims to address that gap by evaluating long-term outcomes in a previously established paediatric cohort.
METHODS: We performed a follow-up analysis of a 2020 cohort at a tertiary paediatric otolaryngology centre. Patients were contacted by letter and SMS to schedule a telephone appointment. Anonymised data, including age, sex, healthcare attendances, interventions and epistaxis frequency, were collected using a standardised proforma. Statistical analysis was performed using R Statistical Software (v4.5.1; R Core Team 2025).
RESULTS: Two hundred and ten patients were scheduled for a telephone appointment and 145 (69.0%) were successfully contacted. Mean age was 13.08 years, with 125 males and 85 females. Median follow-up was 48 months. Among the 75 patients (51.7%) who reported persistent epistaxis, 65.3% (n = 49) had not sought any further medical care. Persistent epistaxis was reported in 44.1% (n = 30) of patients treated with Naseptin alone, compared to 57.6% (n = 30) of those who also received silver nitrate cautery. There was no significant difference in the rate of recurrence between Naseptin and added cautery.
CONCLUSION: Persistent epistaxis was common, with no significant difference between treatment with Naseptin alone and those who also received silver nitrate cautery. Patient/parent education is essential to explain the aetiology of recurrent paediatric epistaxis, its natural history and appropriate first aid.
METHODS: We performed a follow-up analysis of a 2020 cohort at a tertiary paediatric otolaryngology centre. Patients were contacted by letter and SMS to schedule a telephone appointment. Anonymised data, including age, sex, healthcare attendances, interventions and epistaxis frequency, were collected using a standardised proforma. Statistical analysis was performed using R Statistical Software (v4.5.1; R Core Team 2025).
RESULTS: Two hundred and ten patients were scheduled for a telephone appointment and 145 (69.0%) were successfully contacted. Mean age was 13.08 years, with 125 males and 85 females. Median follow-up was 48 months. Among the 75 patients (51.7%) who reported persistent epistaxis, 65.3% (n = 49) had not sought any further medical care. Persistent epistaxis was reported in 44.1% (n = 30) of patients treated with Naseptin alone, compared to 57.6% (n = 30) of those who also received silver nitrate cautery. There was no significant difference in the rate of recurrence between Naseptin and added cautery.
CONCLUSION: Persistent epistaxis was common, with no significant difference between treatment with Naseptin alone and those who also received silver nitrate cautery. Patient/parent education is essential to explain the aetiology of recurrent paediatric epistaxis, its natural history and appropriate first aid.